RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
about
DNA repair targeted therapy: The past or future of cancer treatment?Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseThe Tumor-Associated Variant RAD51 G151D Induces a Hyper-Recombination PhenotypeRAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells.Gene expression profiling reveals activation of the FA/BRCA pathway in advanced squamous cervical cancer with intrinsic resistance and therapy failureAssociating transcriptional modules with colon cancer survival through weighted gene co-expression network analysis.A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair.Treatment Outcome and Prognostic Molecular Markers of Supratentorial Primitive Neuroectodermal Tumors.Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.Polymorphism within the distal RAD51 gene promoter is associated with colorectal cancer in a Polish population.High RAD54B expression: an independent predictor of postoperative distant recurrence in colorectal cancer patientsHigh levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon CancerGenomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma.Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.Targeting homologous recombination-mediated DNA repair in cancer.Personalised Medicine: Genome Maintenance Lessons Learned from Studies in Yeast as a Model Organism.RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies.Rosiglitazone enhances radiosensitivity by inhibiting repair of DNA damage in cervical cancer cells.Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.RAD51 regulates CHK1 stability via autophagy to promote cell growth in esophageal squamous carcinoma cells.Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.DNA-damage related genes and clinical outcome in hormone receptor positive breast cancerRADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.β1-integrin impacts Rad51 stability and DNA double-strand break repair by homologous recombination.Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair.Inhibition of RAD51 by siRNA and Resveratrol Sensitizes Cancer Stem Cells Derived from HeLa Cell Cultures to Apoptosis.DNA Repair.RPA and RAD51: fork reversal, fork protection, and genome stability
P2860
Q26768679-423C8BF1-7F8B-4C18-8B1E-62FA5B8C8B48Q28540624-9D6A5D67-DA15-4798-B23F-52EB0F5142DBQ28553470-258E44F4-11C6-4262-8913-D422D991D7E2Q30365298-6CD0646D-CE21-457E-BA29-FA587AFF1193Q30578079-EE8B7EA2-B06D-4794-9020-FE5A86ECBBACQ33655335-6B4047E8-0A8D-460E-91BE-810D5325B809Q33817458-5E2B1D79-415A-4BA5-9228-2BCC5D98B27AQ35613493-4BCCFC89-295A-442B-8B07-18C127CC9A3AQ35988515-2DA6ECEE-F553-4469-B323-77B8BF3ED000Q36144711-7612ED5C-B944-4DAF-9C69-37C265CE4C6DQ36261964-F807B5D2-E648-4D89-9140-D14E55740FD6Q36356237-63EE4F6B-BD4D-4FBC-8A86-D3ACAA848FFDQ36780751-F3E71B7B-9A88-4A59-93D7-963E760A10CAQ36919195-8021E3CF-37B9-43A5-9678-B3828E4A5B17Q37109905-94043E03-DF8A-4D19-A13C-FADB673777E9Q37672120-33389630-09E4-4923-939E-3AAB0BF91832Q37688471-DAE3E724-86A1-4D6D-BBE6-96ED0ACF04D0Q38106985-C615AEB8-BD73-4739-B95E-2E694DDC08BDQ38184667-88F3AEF6-D7F2-4367-8460-74F23797EF84Q38608688-B6E3C592-E67B-4692-A1E4-3FB8F29D8F1BQ38801052-A31BF0DA-4DF1-43B8-908A-54B05DA248FCQ38873958-B6A04FFA-62CE-4D03-99B2-8608914223FCQ38973740-9DB6BCD1-64F9-4CBB-A589-0CD09D1E7517Q39289111-20006C67-CDC6-4B2B-A5DB-53348E099A18Q40038637-B13B8BEF-80F2-4136-A8E2-0C1248B9FE39Q41881917-A6BE824F-FE47-4CDE-ABFD-1A12C0BBB687Q42362638-B9D59BDE-C78D-4D37-9FD6-FADEE4350219Q42428356-1CC9F46A-C957-4DE6-BCDB-DE2E9BC588CEQ47763209-1D10C6D2-1DDC-44D9-B265-D3E8A4E214D0Q49791143-2B650512-20FA-46EC-A366-ABD3B40154F9Q51504437-F160A645-1BCD-4EFB-9329-6120974DAFC5Q52571383-B1917649-E7B7-458B-B7D1-701F522B9983Q52863441-967376A4-17ED-4A44-8302-8574A0F1D430Q57753904-AE9F7D0B-7C41-4216-9C47-C729E5B78EBA
P2860
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
@en
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
@nl
type
label
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
@en
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
@nl
prefLabel
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
@en
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
@nl
P2093
P2860
P356
P1476
RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma.
@en
P2093
Andreas Marx
Cordula Petersen
Ekkehard Dikomey
Guido Sauter
Kerstin Borgmann
Luigi Terracciano
Pierre Tennstedt
Robert Fresow
Ronald Simon
P2860
P304
P356
10.1002/IJC.27907
P577
2012-11-05T00:00:00Z